A randomised, double-blind, placebo-controlled study of the efficacy and safety of a diclofenac sodium patch for the topical treatment of acute pain due to mild to moderate soft tissue injuries.
Year: 2009
Type: Pharmaceutical - Pain
Phase: III
Indication: Pain - General
A Multicentre, Randomised, Double-Blind, Parallel Group Comparison of The Efficacy and Safety of Transdermal Buprenorphine (Norspan® TDS) And Placebo in Participants with Post Herpetic Neuralgia.
Year: 2010
Type: Pharmaceutical - Pain
Phase: III, IV
Indication: Postherpetic Neuralgia
Open-label study to evaluate the Long-Term Safety of Subcutaneous MOA-728 for Treatment of Opioid-Induced Constipation in Subjects with Non-malignant Pain.
Year: 2010
Type: Pharmaceutical - Pain
Phase: III
Indication: Pain - General
A confirmatory, placebo-controlled, randomised, double-blind, single dummy, parallel group, ratio-finding study in constipated pain patients to establish an optimal Hydromorphone – naloxone ratio with an improved bowel function and a comparable analgesic efficacy compared to Hydromorphone alone.
Year: 2011
Type: Pharmaceutical - Pain
Phase: II, III
Indication: Pain - General
A randomised, double-blind, double-dummy, parallel-group multicentre study to demonstrate improvement in symptoms of constipation and noninferiority in analgesic efficacy in subjects with non-malignant or malignant pain that requires around-the-clock opioid therapy taking 50/25 – 80/40 mg twice daily as oxycodone/naloxone prolonged release (OXN PR) tablets compared to subjects taking 50 – 80 mg twice daily oxycodone prolonged release (OxyPR) tablets alone.
Year: 2012
Type: Pharmaceutical - Pain
Phase: III
Indication: Pain - General
CREATE-1: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-02 (Disodium Zoledronate Tetrahydrate) Administered Orally to Subjects with Complex Regional Pain Syndrome Type I (CRPS-I).
Year: 2016
Type: Pharmaceutical - Pain
Phase: III
Indication: CRPS
A multi-centre, randomised, double-blind, placebo-controlled, parallel group, multiple dose, study of the efficacy of 8.75mg Flurbiprofen micro granules in the relief of sore throat due to upper respiratory tract infection.
Year: 2009
Type: Pharmaceutical - Other
Phase: III
Indication: Other
A Multi-Centre, Randomised, Double-Blinded, Placebo Controlled, Parallel Group, Multiple Dose Study of the Efficacy of 8.75mg Flurbiprofen Spray in the Relief of Sore Throat due to URTI.
Year: 2012
Type: Pharmaceutical - Other
Phase: III
Indication: Other
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active- Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder.
Year: 2013
Type: Pharmaceutical - Other
Phase: III
Indication: Overactive Bladder
A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive Bladder.
